Table 5

Clinical details of the aHUS patients with factor H autoantibodies

Patient IDAge at presentation, ySexClinical outcomeLength of follow-up, yTransplantedC3, g/LC4, g/LFactor H, g/LFactor I, mg/L
1 5 M Recovered renal function. 2 relapses. On PE 2×/week 2 No 0.61 0.1 0.37 39 
2 11 M Recovered renal function 5 No 0.57 0.15 0.44 70 
3 8 F ESRF 9 No 0.86 0.25 0.49 58 
4 4 F ESRF 1 No 0.89 0.3 0.52 41 
5 10 F ESRF 5 Yes, 3 y no recurrence 0.92 0.2 0.29 n/a 
6 8 M ESRF 6 No 1.08 0.36 0.5 74 
7 6 M ESRF 7 Yes, 2 years no recurrence 0.77 0.28 0.56 77 
8 1 M Recovered renal function 4 No 1.59 0.38 0.67 75 
9 9 F Recovered renal function 11 No n/a n/a 0.63 n/a 
10 5 M Recovered renal function; multiple relapses; PE 1×/2 weeks 3 No 1.06 0.13 0.45 68 
11 4 F Recovered renal function; 3 relapses treated with PE 6 No 0.85 0.24 n/a n/a 
12 10 F ESRF 8 Yes, 6 y no recurrence 0.51 0.23 0.57 62 
13 9 F Recovered renal function 8 No n/a n/a n/a n/a 
Patient IDAge at presentation, ySexClinical outcomeLength of follow-up, yTransplantedC3, g/LC4, g/LFactor H, g/LFactor I, mg/L
1 5 M Recovered renal function. 2 relapses. On PE 2×/week 2 No 0.61 0.1 0.37 39 
2 11 M Recovered renal function 5 No 0.57 0.15 0.44 70 
3 8 F ESRF 9 No 0.86 0.25 0.49 58 
4 4 F ESRF 1 No 0.89 0.3 0.52 41 
5 10 F ESRF 5 Yes, 3 y no recurrence 0.92 0.2 0.29 n/a 
6 8 M ESRF 6 No 1.08 0.36 0.5 74 
7 6 M ESRF 7 Yes, 2 years no recurrence 0.77 0.28 0.56 77 
8 1 M Recovered renal function 4 No 1.59 0.38 0.67 75 
9 9 F Recovered renal function 11 No n/a n/a 0.63 n/a 
10 5 M Recovered renal function; multiple relapses; PE 1×/2 weeks 3 No 1.06 0.13 0.45 68 
11 4 F Recovered renal function; 3 relapses treated with PE 6 No 0.85 0.24 n/a n/a 
12 10 F ESRF 8 Yes, 6 y no recurrence 0.51 0.23 0.57 62 
13 9 F Recovered renal function 8 No n/a n/a n/a n/a 

aHUS indicates atypical hemolytic uremic syndrome; ESRF, end-stage renal failure; F, female; M, male; n/a, not available; and PE, plasma exchange.

View Large